HC Wainwright Forecasts Q32 Bio’s Q3 Earnings (NASDAQ:QTTB)

Q32 Bio Inc. (NASDAQ:QTTB) – Research analysts at HC Wainwright upped their Q3 2026 EPS estimates for shares of Q32 Bio in a research report issued on Wednesday, August 5th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.32) for the quarter, up from their previous estimate of ($0.50). HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Q32 Bio’s Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.56) EPS.

Q32 Bio (NASDAQ:QTTB) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02.

Other equities research analysts also recently issued research reports about the company. Mizuho began coverage on Q32 Bio in a report on Friday, May 22nd. They set an “outperform” rating and a $14.00 price target for the company. Cantor Fitzgerald assumed coverage on Q32 Bio in a research note on Monday, May 18th. They set an “overweight” rating on the stock. Zacks Research downgraded shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Weiss Ratings upgraded shares of Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Finally, Oppenheimer increased their target price on shares of Q32 Bio from $20.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Q32 Bio currently has an average rating of “Moderate Buy” and an average price target of $30.00.

Q32 Bio Stock Down 1.8%

QTTB stock opened at $16.20 on Friday. The firm has a market capitalization of $274.75 million, a PE ratio of 5.40 and a beta of 0.23. The company has a quick ratio of 5.36, a current ratio of 5.36 and a debt-to-equity ratio of 0.04. Q32 Bio has a twelve month low of $1.57 and a twelve month high of $23.57. The stock’s 50 day moving average is $13.85 and its 200-day moving average is $8.43.

Insiders Place Their Bets

In other Q32 Bio news, Director Orbimed Advisors Llc purchased 1,875,000 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were acquired at an average cost of $8.00 per share, for a total transaction of $15,000,000.00. Following the completion of the acquisition, the director owned 3,502,987 shares of the company’s stock, valued at $28,023,896. The trade was a 115.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Diyong Xu acquired 1,875,000 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $15,000,000.00. Following the transaction, the director owned 3,502,987 shares of the company’s stock, valued at approximately $28,023,896. The trade was a 115.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 34.46% of the company’s stock.

Hedge Funds Weigh In On Q32 Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in QTTB. Opaleye Management Inc. purchased a new position in Q32 Bio in the fourth quarter valued at approximately $708,000. Renaissance Technologies LLC grew its holdings in Q32 Bio by 107.7% during the first quarter. Renaissance Technologies LLC now owns 206,915 shares of the company’s stock valued at $1,328,000 after purchasing an additional 107,315 shares during the period. Jane Street Group LLC purchased a new stake in Q32 Bio in the second quarter worth $69,000. AQR Capital Management LLC purchased a new stake in Q32 Bio in the first quarter worth $68,000. Finally, Two Sigma Investments LP bought a new stake in shares of Q32 Bio in the third quarter valued at $62,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.